---
layout: default
title: Acetaldehyde Agathosma Betulina Leaf Apis Mellifer
parent: 僅模型預測 (L5)
nav_order: 88
evidence_level: L5
indication_count: 0
---

# Acetaldehyde Agathosma Betulina Leaf Apis Mellifer
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Ingredient Homeopathic Urinary Preparation: No Predicted Indication Available

## One-Sentence Summary

This Evidence Pack describes a complex 25-ingredient preparation whose components span plant extracts, animal-derived materials, mineral salts, bacterial nosodes, and pig urogenital tissues — a profile consistent with homeopathic urinary-tract formulations.
The TxGNN model returned **no predicted new indications** for this candidate, and the preparation holds **no regulatory approvals** in the United States.
Without a mapped DrugBank entry, a verified original indication, or model output, evidence level cannot be formally assessed and the evaluation cannot proceed beyond triage.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available (0 US licenses; product not marketed) |
| Predicted New Indication | None (TxGNN returned no predictions) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — model prediction only, no supporting studies |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No TxGNN prediction was generated for this candidate, so a mechanistic rationale for a new indication cannot be constructed.

Based on the ingredient profile alone, this preparation appears to be a **homeopathic or complex botanical-nosode formulation** targeting the urinary tract. Several lines of circumstantial evidence support this interpretation:

- **Urinary-tract botanicals**: Agathosma betulina (buchu), Orthosiphon aristatus (Java tea), Solidago virgaurea (goldenrod), and Equisetum hyemale (horsetail) are all traditionally used for lower urinary-tract complaints.
- **Homeopathic nosodes and organ preparations**: Escherichia coli, Shigella dysenteriae, and the four Sus scrofa urogenital tissues (renal pelvis, ureter, urethra, urinary bladder) are characteristic nosode/sarcodes of classical homeopathic UTI formulas.
- **Traditional antimicrobials**: Lytta vesicatoria (Cantharis), mercuric chloride, silver nitrate, and cupric sulfate have historical homeopathic use in urinary inflammation and dysuria.

Currently, detailed mechanism-of-action data is not available, and no DrugBank ID was resolved for this multi-ingredient combination. Because the preparation has not been mapped to a single pharmacological entity, TxGNN — which operates on individual drug nodes within a knowledge graph — could not generate a prediction.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## US Market Information

This preparation holds no US NDA, BLA, or ANDA approvals. The TFDA query likewise returned zero records. No authorization table can be generated.

---

## Safety Considerations

Please refer to the package insert for safety information.

> **Note on high-concern ingredients**: Several components in this preparation carry inherent toxicological concerns at non-homeopathic concentrations, including **mercuric chloride** (nephrotoxic heavy metal), **silver nitrate** (caustic), **turpentine oil** (nephrotoxic, CNS toxin), **Lytta vesicatoria / cantharidin** (vesicant, nephrotoxic), and **Chondrodendron tomentosum** (curare source, neuromuscular blocker). Before any clinical evaluation, concentration and dosage data must be obtained and reviewed for each ingredient.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This candidate cannot advance through standard drug-repurposing evaluation because it lacks a DrugBank ID, a verified original indication, and any TxGNN prediction output. The complex multi-ingredient structure — characteristic of homeopathic or traditional combination products — falls outside the single-entity model assumptions of TxGNN, explaining the empty prediction result. Toxicological uncertainty around several ingredients (mercury, cantharidin, turpentine) adds an additional safety barrier.

**To proceed, the following is needed:**

- **Product identity clarification**: Determine whether this is a registered homeopathic product (e.g., HPUS or European Homeopathic Pharmacopoeia entry) and obtain the brand name, manufacturer, and licensed indication.
- **Ingredient concentrations and dosage form**: Homeopathic dilution levels (e.g., 6C, 12X) are critical context — they determine whether toxic components pose any pharmacological risk.
- **DrugBank / ingredient mapping**: Map each of the 25 ingredients individually to DrugBank or ChEBI identifiers so that TxGNN can evaluate each component separately.
- **MOA data**: Query DrugBank, PubChem, and the primary literature for each bioactive component (quercetin, cantharidin, berberine from Berberis, etc.).
- **TFDA/US FDA safety package**: Download and parse the package insert PDF (or homeopathic drug listing) to populate warnings and contraindications.
- **Re-run TxGNN per ingredient**: After individual ingredient mapping, re-submit each mapped component to the TxGNN pipeline to generate per-ingredient repurposing predictions, then aggregate results.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

